Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
Abstract Objective The potential of immune-related adverse events (irAEs) in predicting the efficacy of PD-1 inhibitors in advanced non-small-cell lung cancer (NSCLC) has rarely been assessed. This study investigated the associations between irAEs and the clinical efficacy of PD-1 inhibitors combina...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13220-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112513111883776 |
|---|---|
| author | Xiaowan Xie Yuhao Li Qiaomei Lv Wei Wang Wenbo Ding Yuanyuan Li |
| author_facet | Xiaowan Xie Yuhao Li Qiaomei Lv Wei Wang Wenbo Ding Yuanyuan Li |
| author_sort | Xiaowan Xie |
| collection | DOAJ |
| description | Abstract Objective The potential of immune-related adverse events (irAEs) in predicting the efficacy of PD-1 inhibitors in advanced non-small-cell lung cancer (NSCLC) has rarely been assessed. This study investigated the associations between irAEs and the clinical efficacy of PD-1 inhibitors combination therapy in patients with advanced NSCLC. Methods A retrospective analysis was conducted of 73 patients with advanced NSCLC receiving PD-1 inhibitors combination therapy from January 2022 and July 2023. Patients were divided into two cohorts: patients with irAEs and patients without irAEs. We conducted an analysis to investigate the impact of irAEs on these different clinical outcomes. Results There were no significant differences observed in clinical characteristics between the two cohorts, except for smoking status (P = 0.011).The cohort with irAEs exhibited a higher objective response rate (ORR) and disease control rate (DCR) compared to the cohort without irAEs (ORR: 32.5% vs 12.1%, P = 0.040; DCR: 80.0% vs 48.5%, P = 0.010).Moreover, the median progression-free survival (PFS) and overall survival (OS) were significantly better in the cohort with irAEs compared to the cohort without irAEs (PFS: 12.4 months vs 6.8 months, P = 0.009; OS: not reached vs 18.3 months, P = 0.024). Additionally, the multivariate COX regression analysis revealed that mild irAEs (PFS: HR = 0.386, 95% CI: 0.199–0.748, P = 0.005; OS: HR = 0.300, 95% CI: 0.105–0.855, P = 0.024) and single-system irAEs (PFS: HR = 0.401, 95% CI: 0.208–0.772, P = 0.006; OS: HR = 0.264, 95% CI: 0.090–0.776, P = 0.015) were identified as independent prognostic factors for both PFS and OS. Conclusions IrAEs, especially thyroid irAEs, as well as mild or single-system irAEs, may serve as predictors of improved efficacy in advanced NSCLC patients receiving PD-1 inhibitors combination therapy. |
| format | Article |
| id | doaj-art-b48d0b7fd7a54a40957c40137f11a787 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-b48d0b7fd7a54a40957c40137f11a7872024-12-22T12:31:30ZengBMCBMC Cancer1471-24072024-12-0124111010.1186/s12885-024-13220-7Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapyXiaowan Xie0Yuhao Li1Qiaomei Lv2Wei Wang3Wenbo Ding4Yuanyuan Li5Department of Oncology, Dandong Central Hospital, China Medical UniversityDepartment of Orthopedics, Dandong Central Hospital, China Medical UniversityDepartment of Oncology, Dandong Central Hospital, China Medical UniversityDepartment of Orthopedics, Dandong Central Hospital, China Medical UniversityDepartment of Orthopedics, Dandong Central Hospital, China Medical UniversityDepartment of Oncology, Dandong Central Hospital, China Medical UniversityAbstract Objective The potential of immune-related adverse events (irAEs) in predicting the efficacy of PD-1 inhibitors in advanced non-small-cell lung cancer (NSCLC) has rarely been assessed. This study investigated the associations between irAEs and the clinical efficacy of PD-1 inhibitors combination therapy in patients with advanced NSCLC. Methods A retrospective analysis was conducted of 73 patients with advanced NSCLC receiving PD-1 inhibitors combination therapy from January 2022 and July 2023. Patients were divided into two cohorts: patients with irAEs and patients without irAEs. We conducted an analysis to investigate the impact of irAEs on these different clinical outcomes. Results There were no significant differences observed in clinical characteristics between the two cohorts, except for smoking status (P = 0.011).The cohort with irAEs exhibited a higher objective response rate (ORR) and disease control rate (DCR) compared to the cohort without irAEs (ORR: 32.5% vs 12.1%, P = 0.040; DCR: 80.0% vs 48.5%, P = 0.010).Moreover, the median progression-free survival (PFS) and overall survival (OS) were significantly better in the cohort with irAEs compared to the cohort without irAEs (PFS: 12.4 months vs 6.8 months, P = 0.009; OS: not reached vs 18.3 months, P = 0.024). Additionally, the multivariate COX regression analysis revealed that mild irAEs (PFS: HR = 0.386, 95% CI: 0.199–0.748, P = 0.005; OS: HR = 0.300, 95% CI: 0.105–0.855, P = 0.024) and single-system irAEs (PFS: HR = 0.401, 95% CI: 0.208–0.772, P = 0.006; OS: HR = 0.264, 95% CI: 0.090–0.776, P = 0.015) were identified as independent prognostic factors for both PFS and OS. Conclusions IrAEs, especially thyroid irAEs, as well as mild or single-system irAEs, may serve as predictors of improved efficacy in advanced NSCLC patients receiving PD-1 inhibitors combination therapy.https://doi.org/10.1186/s12885-024-13220-7Advanced nonSmallCell lung cancerPD- 1 inhibitors combination therapyImmune related adverse eventsClinical efficacy |
| spellingShingle | Xiaowan Xie Yuhao Li Qiaomei Lv Wei Wang Wenbo Ding Yuanyuan Li Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy BMC Cancer Advanced non Small Cell lung cancer PD- 1 inhibitors combination therapy Immune related adverse events Clinical efficacy |
| title | Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy |
| title_full | Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy |
| title_fullStr | Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy |
| title_full_unstemmed | Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy |
| title_short | Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy |
| title_sort | immune related adverse events correlate with the clinical efficacy in advanced non small cell lung cancer patients treated with pd 1 inhibitors combination therapy |
| topic | Advanced non Small Cell lung cancer PD- 1 inhibitors combination therapy Immune related adverse events Clinical efficacy |
| url | https://doi.org/10.1186/s12885-024-13220-7 |
| work_keys_str_mv | AT xiaowanxie immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy AT yuhaoli immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy AT qiaomeilv immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy AT weiwang immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy AT wenboding immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy AT yuanyuanli immunerelatedadverseeventscorrelatewiththeclinicalefficacyinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorscombinationtherapy |